Friday, March 24, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Funding News

Development of In Vitro Technologies for Evaluation of CBRN Countermeasures

by Global Biodefense Staff
May 20, 2013

Test Tubes of Colored LiquidThe Defense Threat Reduction Agency is seeking concepts for advanced development of in vitro technologies to support rapid development of chemical and biological threat agent Medical Countermeasures (MCMs).

Current pre-clinical study methods for obtaining safety, efficacy and pharmacokinetics of MCMs rely almost exclusively on experimental models that frequently have limited correlation to the human condition and often do not accurately predict tolerability and safety in human subjects.

DTRA envisions a platform utilizing human immune cells organized in a physiological relevant manner that can provide additional and improved information on the expected immune response in humans treated with MCMs. Such technology would reduce the overall burden of in vivo testing in the development and management of products for human use.

The system should be comprised of a series of sensitive and reliable culture assays for the interrogation of human innate and adaptive immunity. The engineered tissue constructs should be comprised of isolated primary human immune cells, principally of blood origin, integrated into engineered constructs that are functionally equivalent to the physiological environment of the human immune system and designed to simulate the environment and cellular communication necessary for the proper induction of immune responses under physiologic conditions.

These constructs should be modular in nature; each one functioning independently as a minimal model of localized immunity against antigens, vaccines, pathogens, or inflammatory signals or they can be coupled to provide a comprehensive picture of immunity. The modular nature of this system should make the technology suitable for a variety of applications:

Dissect the mechanisms of action of vaccines and adjuvants
Define the cellular and humoral correlates of protection, as well as provide insight into the mechanisms of antibody mediated pathogen neutralization
Assess relative changes in vaccine immunogenicity and efficacy between various manufacturing processes, vaccine lots, etc.
Monitor the effects of human genetic and environmental diversity on the induction of immunity since we can test across all populations or targeted populations with our donor pool

Responders should discuss the development or existence of sensitive and cost-effective target-cell based functional assays that can be used to determine whether antibodies generated by their technology are able to block or neutralize a pathogen of interest. Advanced assays, which evaluate antibody (Ab) functionality, should be addressed. Specifically, bead technology that permits an assessment of the quantity and quality of Abs generated against a wide panel of Ags simultaneously in a small volume (20-50 μl) is desired.

Further details are available under Solicitation Number: HDTRA1-13-RFI-CBM01. The response deadline is June 17, 2013.

Tags: Defense Threat Reduction AgencyRFI

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions
Pathogens

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
Load More

Latest News

Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC